EPCAM and neoplasm: To briefly explain its principles, EpCAM + cells were targeted immunomagnectically during the enrichment process and then the events with cytokeratins (CKs) 8+, 18+, 19+ 4′,6-Diamidino-2-Phenylindole (DAPI) + CD45- were identified as circulating tumor cells7, 62, 63.